INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is one of the most common malignancies worldwide \[[@R1]\]. CRC has been increasing annually in Japan, and was estimated to be the most common malignancy in 2016 and the second most common cause of cancer-related deaths in 2014 \[[@R2]\].

Recurrence rates vary among patients who receive curative surgery, with recurrence reported in about 30% of stage III patients, 15% of stage II patients, and \<5% of stage I patients in Japan \[[@R3]\]. Adequate surveillance is therefore required to both reduce costs and improve survival. However, surveillance is generally provided for patients without any recurrence.

The usefulness of intensive surveillance with routine carcinoembryonic antigen (CEA) monitoring and computed tomography (CT) scans remains controversial. Although early detection of recurrence has been shown to improve survival, early detection using intensive surveillance did not always result in improved overall survival \[[@R4]--[@R9]\]. The guidelines of the Japanese Society for Cancer of the Colon and Rectum propose intensive surveillance, including CEA checks every 3 months and CT every 6 months for 3 years, regardless of clinical stage and risk of recurrence \[[@R10]\]. This reflects the intensive surveillance schedules recommended by the European Society for Medical Oncology, American Society of Clinical Oncology, and National Comprehensive Cancer Network (NCCN) guidelines, which recommended CEA checks every 3--6 months and CT every 6--12 months for 2--3 years, depending on the risk of the patient \[[@R11]--[@R15]\].

However, these surveillances are not strictly categorized by risk factors other than clinical stage. Information on time to recurrence (TTR) and survival after recurrence (SAR) may help to determine the appropriate follow-up schedule, and has previously been used to evaluate the usefulness of intensive follow-up in clinical trials and meta-analysis \[[@R3], [@R5], [@R7], [@R8]\].

In this study, we evaluated the clinicopathological factors predicting TTR and SAR in patients with colon cancer (CC) or rectal cancer (RC) during intensive follow-up after curative resection, to determine the factors influencing the appropriate follow-up schedule.

RESULTS {#s2}
=======

Differences in clinicopathological factors between CC and RC {#s2_1}
------------------------------------------------------------

We compared the clinicopathological factors between CC and RC (Table [1](#T1){ref-type="table"}). Age group, gender, preoperative CEA level, tumor depth, nodal status, venous invasion, application of adjuvant therapy, and clinical stage all differed significantly between the two locations.

###### Clinicopathological factors of patients by tumor location

  Location             CC          RC          *P* value   CC      RC         *P* value              
  -------------------- ----------- ----------- ----------- ------- ---------- ----------- ---------- ----------
  Age                                                                                                
    ≤64                1041 (34)   998 (51)    \<0.0001    15.4%   NS         19.3%       NS         0.018
    65--74             1090 (36)   629 (32)    13.1%       21.6%   \<0.0001                          
    75≤                908 (30)    326 (17)    13.4%       18.4%   0.03                              
  Gender                                                                                             
    Male               1678 (55)   1192 (61)   \<0.0001    14.8%   NS         21.4%       0.041      \<0.0001
    Female             1361 (45)   761 (39)    13.0%       17.6%   0.0044                            
  Preoperative CEA                                                                                   
    High               831 (27)    561 (29)    0.043       23.9%   \<0.0001   30.5%       \<0.0001   0.0068
    Normal             2115 (70)   1310 (67)   10.3%       15.3%   \<0.0001                          
    Unknown            93 ( 3)     82 (4)      9.7%        20.7%   0.04                              
  Histological Type                                                                                  
    Well/Moderately    2867 (94)   1881 (96)   0.0069      13.6%   NS         19.2%       0.0002     \<0.0001
    Poorly             74 (2)      31 (2)      21.6%       41.9%   0.034                             
    Mucinous           98 (3)      41 (2)      18.4%       36.6%   0.021                             
  Tumor depth                                                                                        
    T1                 592 (19)    355 (18)    \<0.0001    1.0%    \<0.0001   4.8%        \<0.0001   0.0003
    T2                 447 (15)    438 (22)    3.6%        11.9%   \<0.0001                          
    T3                 1411 (46)   971 (50)    14.0%       25.4%   \<0.0001                          
    T4                 589 (19)    189 (10)    35.0%       38.6%   NS                                
  Nodal status                                                                                       
    N0                 2039 (67)   1256 (64)   \<0.0001    7.9%    \<0.0001   14.1%       \<0.0001   \<0.0001
    N1                 786 (26)    483 (25)    22.3%       26.3%   NS                                
    N2                 214 (7)     214 (119)   41.1%       39.7%   NS                                
  Lymphatic invasion                                                                                 
    ly0                1323 (44)   793 (41)    NS          8.9%    \<0.0001   13.1%       \<0.0001   0.0023
    ly1                1261 (41)   853 (44)    14.9%       21.3%   0.0001                            
    ly2                378 (12)    262 (13)    23.5%       32.4%   0.013                             
    ly3                58 (2)      37 (2)      48.3%       45.9%   NS                                
    Unknown            19 (1)      8 (0)       10.5%       12.5%   NS                                
  Venous invasion                                                                                    
    v0                 1193 (39)   610 (31)    \<0.0001    6.4%    \<0.0001   10.5%       \<0.0001   0.0025
    v1                 1188 (39)   765 (39)    15.3%       19.3%   0.021                             
    v2                 493 (16)    436 (22)    23.5%       30.0%   0.025                             
    v3                 140 (5)     125 (6)     32.1%       35.2%   NS                                
    Unknown            25 (1)      17 (1)      20%         11.8%   NS                                
  Stage                                                                                              
    I                  890 (29)    641 (33)    \<0.0001    1.2%    \<0.0001   8.4%        \<0.0001   \<0.0001
    II                 1149 (38)   614 (31)    13.1%       20.0%   0.0002                            
    III                1000 (33)   697 (36)    26.3%       30.4%   NS                                
  Adjuvant therapy                                                                                   
   Stage I                                                                                           
    Yes                18 (2)      26 (4)      0.019       5.6%    NS         7.7%        NS         NS
    No                 872(98)     615 (96)    1.1%        8.5%    \<0.0001                          
   Stage II                                                                                          
    Yes                184 (16)    126 (20)    0.019       17.9%   0.036      25.4%       NS         NS
    No                 965 (84)    489 (80)    12.2%       18.6%   0.001                             
   Stage III                                                                                         
    Yes                643 (64)    509 (73)    0.0002      25.8%   NS         31.0%       NS         NS
    No                 357 (36)    188 (27)    27.2%       28.7%   NS                                

CEA: Carcinoembryonic antigen, CC: colon cancer, NS: Not significant, Poorly: poorly differentiated adenocarcinoma, Mucinous: mucinous adenocarcinoma.

RC: rectal cancer, Well/Moderately: well differentiated/moderately differentiated adenocarcinoma.

Factors associated with recurrence {#s2_2}
----------------------------------

The recurrence rates of stages I, II, and III CC were 1.2% (11/890), 13.1% (151/1149), and 26.3% (263/1000), and of RC were 8.4% (54/641), 20.0% (123/614), and 30.4% (212/697), respectively (Table [1](#T1){ref-type="table"}). High preoperative CEA level, tumor depth, nodal status, lymphatic invasion, venous invasion, and clinical stage were significantly associated with recurrence, regardless of tumor location (Table [1](#T1){ref-type="table"}). Gender and histological type were significantly associated with recurrence in RC, but not in CC.

We also assessed the influence of tumor location on recurrence in relation to each clinicopathological factor (Table [1](#T1){ref-type="table"}). There were significant differences in recurrence rates between CC and RC for patients in each age group, with each CEA level, each histological type, and with tumor depth of T1-3, N0 nodal status, lymphatic invasion of ly0-2, venous invasion of v0-2, stage I-II and stage I-II without adjuvant therapy. However, there were no significant differences in recurrence rates by tumor location in relation to clinically-advanced factors including: depth of T4, N1 and N2 nodal status, lymphatic invasion of ly3, venous invasion of v3, and stage III.

Factors associated with RFS and OS {#s2_3}
----------------------------------

RFS was significantly influenced by preoperative CEA level, histological type, tumor depth, nodal status, stage, lymphatic invasion, and venous invasion, regardless of tumor location (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). RFS was also significantly influenced by gender in patients with RC (Figure [2](#F2){ref-type="fig"}). OS was significantly influenced by age, gender, preoperative CEA level, tumor depth, nodal status, stage, lymphatic invasion, and venous invasion, regardless of tumor location (Figures [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). OS was also significantly influenced by histological type in RC alone (Figure [4](#F4){ref-type="fig"}).

![Relapse-free survival (RFS) in colon cancer according to **(A)** age, **(B)** gender, **(C)** CEA level, **(D)** histological type, **(E)** tumor depth, **(F)** nodal status, **(G)** clinical stage, **(H)** lymphatic invasion, and **(I)** venous invasion. Subgroups were compared with log-rank test. P values were provided when differences were significant (P\<0.05) and as NS when differences were not significant.](oncotarget-09-25474-g001){#F1}

![Relapse-free survival (RFS) in rectal cancer according to **(A)** age, **(B)** gender, **(C)** CEA level, **(D)** histological type, **(E)** tumor depth, **(F)** nodal status, **(G)** clinical stage, **(H)** lymphatic invasion, and **(I)** venous invasion. Subgroups were compared with log-rank test. P values were provided when differences were significant (P\<0.05) and as NS when differences were not significant.](oncotarget-09-25474-g002){#F2}

![Overall survival (OS) in colon cancer according to **(A)** age, **(B)** gender, **(C)** CEA level, **(D)** histological type, **(E)** tumor depth, **(F)** nodal status, **(G)** clinical stage, **(H)** lymphatic invasion, and **(I)** venous invasion. Subgroups were compared with log-rank test. P values were provided when differences were significant (P\<0.05) and as NS when differences were not significant.](oncotarget-09-25474-g003){#F3}

![Overall survival (OS) in rectal cancer according to **(A)** age, **(B)** gender, **(C)** CEA level, **(D)** histological type, **(E)** tumor depth, **(F)** nodal status, **(G)** clinical stage, **(H)** lymphatic invasion, and **(I)** venous invasion. Subgroups were compared with log-rank test. P values were provided when differences were significant (P\<0.05).](oncotarget-09-25474-g004){#F4}

Clinicopathological factors in patients with recurrence {#s2_4}
-------------------------------------------------------

Age group, gender, tumor depth, nodal status, stage, TTR, type of recurrence, and sites of recurrence differed significantly between CC and RC in patients with recurrence (Table [2](#T2){ref-type="table"}). The liver was the most common metastatic site in CC patients, followed by the lungs, peritoneum, and distant lymph nodes. In contrast, the lungs were the most common metastatic site in RC patients, followed by the liver, local recurrence, and distant lymph nodes. There was no significant difference in preoperative CEA, histological type, or treatment after recurrence according to tumor location.

###### Clinicopathological factors of patients with recurrence by tumor location

  --------------------------------------------------------------------------------------------------------------
  Factors / Location                                  CC (N=425)\        RC (N=389)\        *P* value CC vs RC
                                                      Number (%)         Number (%)         
  --------------------------------------------------- ------------------ ------------------ --------------------
  Age                                                                                       

   ≤64 / 65--74/ 75≤                                  160/143/122\       193/136/60\        \<0.0001
                                                      (38/33/29)         (50/35/15)         

  Gender                                                                                    

   Male / Female                                      248/177\           255/134\           0.035
                                                      (58/42)            (66/34)            

  Preoperative CEA                                                                          

   High / Normal / Unknown                            199/217/9\         171/201/17\        NS
                                                      (47/51/2)          (44/52/4)          

  Histological Type                                                                         

   Well/Moderately / Poorly /Mucinous                 391/16/18\         361/13/15\         NS
                                                      (92/2/2)           (93/3/4)           

  Tumor depth                                                                               

   T1 / T2 / T3 / T4                                  6/16/197/206\      17/52/247/73\      \<0.0001
                                                      (1/4/46/48)        (4/13/63/19)       

  Nodal status                                                                              

   N0 / N1 / N2                                       162/175/88\        177/127/85\        0.034
                                                      (38/41/21)         (46/33/22)         

  Lymphatic invasion                                                                        

   ly0 / ly1 / ly2 / ly3/Unknown                      118/188/89/28/2\   104/182/85/17/1\   NS
                                                      (28/44/21/7/1)     (27/47/22/4/0)     

  Venous invasion                                                                           

   v0 / v1 / v2 / v3 / Unknown                        77/182/116/45/5\   64/148/131/44/2\   NS
                                                      (18/43/27/11/1)    (16/38/34/11/1)    

  Stage                                                                                     

   I / II / III                                       11/151/263\        54/123/212\        \<0.0001
                                                      (3/36/62)          (14/32/54)         

  Time to recurrence (year)                                                                 

   \< 1 / 1--2/ 2--3 / 3≤                             190/136/64/35\     142/122/57/68\     0.0007
                                                      (45/32/15/8)       (37/31/15/17)      

  Type of recurrence                                                                        

   Local alone /M1a / M1b                             29/251/145\        77/243/69\         \<0.0001
                                                      (7/59/34)          (20/62/18)         

  Liver metastasis                                                                          

   (+) / (-)                                          203/222\           128/261\           \<0.0001
                                                      (48/52)            (33/67)            

  Lung metastasis                                                                           

   (+) / (-)                                          130/295\           148/241\           0.025
                                                      (31/69)            (38/62)            

  Peritoneal metastasis                                                                     

   (+) / (-)                                          83/342\            28/361\            \<0.0001
                                                      (20/80)            (7/93)             

  Local metastasis                                                                          

   (+) / (-)                                          41/384\            112/277\           \<0.0001
                                                      (10/90)            (29/71)            

  Distant lymph node metastasis                                                             

   (+) / (-)                                          63/362\            45/344\            NS
                                                      (15/85)            (12/88)            

  Adjuvant therapy                                                                          

   (+) / (-)                                          200/225\           192/197\           NS
                                                      (47/53)            (49/51)            

  Treatment after recurrence                                                                

   Best supportive care / Surgery (-) / Surgery (+)   38/188/199\        30/167/192\        NS
                                                      (9/44/47)          (8/43/49)          
  --------------------------------------------------------------------------------------------------------------

CEA: Carcinoembryonic antigen, CC: colon cancer, Mucinous: mucinous adenocarcinoma, NS: Not significant, Poorly: poorly differentiated adenocarcinoma, RC: rectal cancer, Well/Moderately: well differentiated/moderately differentiated adenocarcinoma

Time to recurrence (TTR) {#s2_5}
------------------------

TTR was significantly longer in stage III patients with RC compared with CC patients, but not in stage I and II patients (Figure [5A-5C](#F5){ref-type="fig"}). The 1-, 2-, 3-, and 5-year accumulative recurrence rates in CC patients were 18%, 46%, 73%, and 91% for stage I; 46%, 78%, 90% and 99% for stage II; 53%, 80%, 94% and 97% for stage III, respectively (Figure [5D](#F5){ref-type="fig"}). The equivalent recurrence rates in RC patients were 17%, 41%, 65%, and 87% for stage I; 49%, 81%, 94%, and 98% for stage II; 44%, 71%, 83%, and 98% for stage III respectively (Figure [5E](#F5){ref-type="fig"}).

![Time to recurrence (TTR) and accumulative recurrence rate **(A**-**E)**, and survival after recurrence (SAR) and survival rate **(F-J)**, by clinicopathological factors. TTR and accumulative recurrence rate in: (A) stage I patients by colon cancer (CC) and rectal cancer (RC), (B) stage II patients by CC and RC, (C) stage III patients by CC and RC, (D) CC by stage, (E) RC by stage. SAR and survival rate in: (F) stage I patients by CC and RC, (G) stage II patients by CC and RC, (H) stage III patients by CC and RC, (I) CC by stage, (J) RC by stage. Subgroups were compared with log-rank test. P values were provided when differences were significant (P\<0.05) and NS was used when differences were not significant.](oncotarget-09-25474-g005){#F5}

We further assessed TTR for CC and RC patients depending on stage, except for stage I, because there were fewer patients and longer TTR than for the other stages.

TTR in stage II CC was significantly associated with gender, preoperative CEA level, lymphatic invasion, and distant lymph node metastasis (Table [3](#T3){ref-type="table"}). TTR in stage III CC was significantly associated with preoperative CEA level, lymphatic invasion, and venous invasion (Table [3](#T3){ref-type="table"}). Multivariate analysis showed that high preoperative CEA level and lymphatic invasion were independent predictors for short TTR in both stage II and stage III CC (Table [4](#T4){ref-type="table"}).

###### Summary of associations between clinicopathological factors and TTR

  Location                Colon cancer   Rectal cancer                                       
  ----------------------- -------------- --------------- ------ ------- ------ ------ ------ ----------
  Age                                                                                        
   ≤74                    17.5           NS              16.6   NS      16.2   NS     20.0   NS
   75≤                    18.0           13.9            17.4   19                           
  Gender                                                                                     
   Male                   19.6           0.04            16.5   NS      16.9   NS     20.5   NS
   Female                 15.3           14.8            15.3   18.7                         
  Preoperative CEA                                                                           
   High                   14.7           0.02            14.1   0.04    16     NS     18.8   NS
   Normal/Unknown         20.3           17.5            16.7   20.9                         
  Histological Type                                                                          
   Well/Moderately        17.5           NS              16.0   NS      16.3   NS     20.2   NS
   Poorly/Mucinous        20.5           14.1            18     16.7                         
  Tumor depth                                                                                
   T1                     \-             NS              15.3   NS             NS     28.5   NS
   T2                     \-             14.9                   30.7                         
   T3                     19.3           13.9            15.7   19.2                         
   T4                     15.6           15.8            19.2   18.7                         
  Nodal status                                                                               
   N0                     17.7           \-                     NS      16.4   \-            0.03
   N1                     16.3           21.8                                                
   N2                     14.9           16.9                                                
  Lymphatic invasion                                                                         
   ly0/1                  18.5           0.008           16.7   NS      15.8   NS     16.7   NS
   ly2/3                  11.4           15.1            20.4   22.0                         
   ly0-2                  17.8           NS              16.4   0.008   16.4   \-     20.6   0.009
   ly3                    13             10.3            \-     11.9                         
  Venous invasion                                                                            
   v0/1                   18.7           NS              17.2   NS      15.3   NS     22.4   0.02
   v2/3                   15.7           14.0            17.5   17.1                         
   v0-2                   17.9           NS              16.6   0.001   16.3   NS     20.0   NS
   v3                     15.2           9.7             16.9   18.9                         
  Adjuvant therapy                                                                           
   Yes                    16.3           NS              16.9   NS      13.9   NS     19.7   NS
   No                     18.1           14.0            17.3   20.3                         
  Type of recurrence                                                                         
   M1a                    18.8           NS              15.5   NS      17.4   NS     21.0   0.02
   M1b                    15.0           15.2            13     14.8                         
   Local alone            20.5           23.4            15.7   22.9                         
  Liver metastasis                                                                           
   (-)                    18.6           NS              16.9   NS      18.6   0.01   23.0   \<0.0001
   (+)                    16.8           14.5            13     12.8                         
  Lung metastasis                                                                            
   (-)                    17.2           NS              15.6   NS      15.8   NS     19.4   NS
   (+)                    18.5           16.2            17.6   20.4                         
  Peritoneal metastasis                                                                      
   (-)                    17.8           NS              16.2   NS      16.4   NS     20.2   NS
   (+)                    16.9           14.3            16     17.3                         
  Local recurrence                                                                           
   (-)                    17.6           NS              15.5   NS      16.8   NS     19.4   NS
   (+)                    18.1           18.9            15.4   21.1                         
  Distant LN metastasis                                                                      
   (-)                    18.3           0.04            15.2   NS      27.7   0.02   19.8   NS
   (+)                    11.9           18.4            15.5   20.4                         

CEA: Carcinoembryonic antigen, LN: lymph node, Mucinous: mucinous adenocarcinoma, NS: Not significant, Poorly: poorly differentiated adenocarcinoma, TTR: time to recurrence, Well/Moderately: well differentiated/moderately differentiated adenocarcinoma.

###### Multivariate analysis of predictors for short TTR

  ---------------------------------------------------------------------------------------------------------------
  Location              Colon cancer   Rectal cancer                                                   
  --------------------- -------------- --------------- ----------- ------ ----------- ---- ----------- ----------
  Gender: Male          0.73\          NS                                                              
                        0.53-1.02                                                                      

  CEA: High             1.47\          0.02            1.34\       0.02                                
                        1.06-2.03                      1.04-1.73                                       

  Nodal status: N2                                                                         1.23\       NS
                                                                                           0.92-1.64   

  Lymphatic invasion                                                                                   

   ly2/3                1.83\          0.04                                                            
                        1.03-3.05                                                                      

   ly3                                                 1.73\       0.02                    1.5\        NS
                                                       1.09-2.64                           0.86-2.45   

  Venous invasion                                                                                      

   v2/3                                                                                    1.42\       0.01
                                                                                           1.07-1.88   

   v3                                                  1.63\       0.02                                
                                                       1.09-2.36                                       

  Type of recurrence:                                                                                  

   M1b                                                                                     1.25\       NS
                                                                                           0.88-1.74   

  Recurrence sites                                                                                     

   Liver (+)                                                              1.44\       NS   1.92\       \<0.0001
                                                                          0.99-2.09        1.41-2.61   

   Distant LN: (+)      1.53\          NS                                 0.52\       NS               
                        0.84-2.61                                         0.23-1.03                    
  ---------------------------------------------------------------------------------------------------------------

CEA: Carcinoembryonic antigen, CI: confidence interval, HR: hazard ratio, LN: lymph node, NS: Not significant, TTR: time to recurrence.

TTR in stage II RC was significantly associated with metastatic factors (liver metastasis and distant lymph node metastasis), but not pathological factors. TTR in stage III RC was significantly associated with both pathological factors (lymphatic invasion and vascular invasion) and metastatic factors (M1b recurrence and liver metastasis) (Table [3](#T3){ref-type="table"}). Multivariate analysis showed that venous invasion and liver metastasis were independent predictors for short TTR in stage III RC (Table [4](#T4){ref-type="table"}).

Survival after recurrence (SAR) {#s2_6}
-------------------------------

The 5-year survival rates after recurrence for CC and RC were 81% and 77% in stage I; 55% and 58% in stage II; 40% and 39% in stage III, respectively (Figure [5F--5H](#F5){ref-type="fig"}). There were significant differences in the 5-year SAR rates among stages, but not between CC and RC (Figure [5F--5J](#F5){ref-type="fig"}).

SAR was significantly associated with age (all groups), gender (stage III RC), CEA level (stage I/II RC), histological type (stage III CRC), tumor depth (CC), nodal status (stage III CC), lymphatic invasion (stage III CRC), adjuvant therapy (stage III RC), recurrence within 1 year (stage III RC), M1b recurrence (stage II/III CRC), liver metastasis (stage II RC), peritoneal metastasis (CC and stage III RC), local recurrence (stage II CC), and treatment after recurrence (all groups) (Table [5](#T5){ref-type="table"}).

###### Summary of associations between clinicopathological factors and SAR

  Location                   Colon cancer   Rectal cancer                                              
  -------------------------- -------------- --------------- ------ ---------- ------ ---------- ------ ----------
  Age                                                                                                  
   ≤74                       59.1           0.0001          46.9   0.005      64.2   0.01       51.1   \<0.0001
   75≤                       33.3           34.1            35.0   24.2                                
  Gender                                                                                               
   Male                      51.9           NS              44.9   NS         59.5   NS         51.6   0.004
   Female                    51.9           41.5            64.7   39.6                                
  Preoperative CEA                                                                                     
   High                      48.8           NS              44.9   NS         46.8   0.049      45.6   NS
   Normal/Unknown            55.4           41.6            67.9   50.0                                
  Histological Type                                                                                    
   Well/Moderately           52.6           NS              45.8   0.003      61.8   NS         50.3   \<0.0001
   Poorly/Mucinous           44.5           18.4            17.4   23.8                                
  Tumor depth                                                                                          
   T1                                       0.009           16     0.002             NS         55     NS
   T2                                       34.7                   42.8                                
   T3                        49.3           53.4            62.8   49.7                                
   T4                        48.4           35.8            55.9   48.0                                
  Nodal status                                                                                         
   N1                                                       47.1   0.02                         50.3   NS
   N2                        36.4           41.5                                                       
  Lymphatic invasion                                                                                   
   ly0/1                     51.4           NS              46.5   NS         63.2   NS         50.7   NS
   ly2/3                     49.6           38.7            37.2   40.7                                
   ly0-2                     53.4           NS              45.5   0.004      61.6   \-         49.2   0.005
   ly3                       14.7           16.3            \-     29.6                                
  Venous invasion                                                                                      
   v0/1                      51.5           NS              44.0   NS         65.8   NS         48.9   NS
   v2/3                      51.3           43.3            54.3   45.6                                
   v0-2                      50.6           NS              44.3   NS         60.7   NS         48.3   NS
   v3                        58.1           38.8            53.7   44.2                                
  Adjuvant therapy                                                                                     
   Yes                       57.0           NS              45.0   NS         65.5   NS         50.9   0.02
   No                        50.9           41.1            58.8   37.7                                
  Time to recurrence                                                                                   
   less than 1 year          48.9           NS              37.8   NS         58.1   NS         41.2   0.004
   more than 1 year          53.0           48.1            62.9   50.4                                
  Type of recurrence                                                                                   
   M1a                       59.0           0.0002          49.8   0.0001     61.2   0.001      53.6   0.0002
   M1b                       43.8           33.6            35.2   29.6                                
   Local alone               42.7           46.8            64.9   43.2                                
  Liver metastasis                                                                                     
   (-)                       46.7           0.01            41.3   NS         60.4   NS         47.4   NS
   (+)                       57.8           46.3            48.9   48.4                                
  Lung metastasis                                                                                      
   (-)                       56.0           NS              42.8   NS         65.9   0.02       46.0   NS
   (+)                       42.7           45.0            46.3   49.0                                
  Peritoneal metastasis                                                                                
   (-)                       54.2           0.03            47.8   \<0.0001   62.5   NS         50.0   0.001
   (+)                       45.2           29.3            15.4   21.8                                
  Local recurrence                                                                                     
   (-)                       54.1           0.04            44.1   NS         59.6   NS         48.3   NS
   (+)                       42.6           41.2            57.0   46.0                                
  Distant LN metastasis                                                                                
   (-)                       53.7           NS              44.5   NS         61.2   NS         49.4   NS
   (+)                       43.1           37.4            66.8   28.9                                
  Therapy after recurrence                                                                             
   Surgical resection (-)    34.2           \<0.0001        32.9   \<0.0001   44.0   \<0.0001   35.1   \<0.0001
   Surgical resection (+)    65.8           57.5            74.4   62.2                                

CEA: Carcinoembryonic antigen, LN: lymph node, NS: Not significant, Mucinous: mucinous adenocarcinoma, Poorly: poorly differentiated adenocarcinoma, SAR: survival after recurrence, Well/Moderately: well differentiated/moderately differentiated adenocarcinoma.

Multivariate analysis identified the following independent prognostic factors: age (stage II CC and stage III RC), female gender (stage III RC), high CEA level (stage II RC), histological type (stage III CRC), nodal status (stage III CC), recurrence within 1 year (stage III RC), M1b recurrence (stage II CRC), local recurrence (stage II CC), and no surgical resection after recurrence (stage II and III CRC) (Table [6](#T6){ref-type="table"}).

###### Multivariate analysis of prognostic factors for SAR

  --------------------------------------------------------------------------------------------------------------------------------------------
  Location                                 Colon cancer   Rectal cancer                                                             
  ---------------------------------------- -------------- --------------- ----------- ---------- ----------- ---------- ----------- ----------
  Age:\                                    2.71\          0.0005          1.33\       NS         1.77\       NS         1.78\       0.04
   75≤                                     1.56-4.67                      0.93-1.9               0.81-3.56              1.03-2.96   

  Gender:\                                                                                                              1.69\       0.009
   Female                                                                                                               1.14-2.47   

  CEA:\                                                                                          2.33\       0.003                  
   High                                                                                          1.34-4.11                          

  Histological type:\                                                     2.04\       0.02                              2.54\       0.005
   Poorly/Mucinous                                                        1.15-3.41                                     1.34-4.54   

  Tumor depth:\                            1.42\          NS              1.32\       NS                                            
   T4                                      0.84-2.43                      0.93-1.87                                                 

  Nodal status:\                                                          1.5\        0.03                                          
   N2                                                                     1.05-2.12                                                 

  Lymphatic invasion:\                                                    1.23\       NS                                            
   ly3                                                                    0.66-2.15                                                 

  Recurrence:\                                                                                                          1.64\       0.01
   within 1 year                                                                                                        1.12-2.4    

  Type of recurrence:\                     2.50\          0.01            1.39\       NS         2.69\       0.008      1.68\       NS
   M1b                                     1.25-4.83                      0.84-2.18              1.31-5.25              0.97-2.78   

  Recurrence sites                                                                                                                  

   Liver (+)                               1.04\          NS                                                                        
                                           0.58-1.84                                                                                

   Lung: (+)                                                                                     1.25\       NS                     
                                                                                                 0.68-2.24                          

   Peritoneal: (+)                         0.74\          NS              1.37\       NS                                1.11\       NS
                                           0.35-1.61                      0.82-2.36                                     0.53-2.27   

   Local: (+)                              3.54\          0.005                                                                     
                                           1.5-7.69                                                                                 

  No adjuvant therapy                                                                                                   1.00\       NS
                                                                                                                        0.64-1.53   

  No surgical resection after recurrence   5.0\           \<0.0001        2.36\       \<0.0001   3.41\       \<0.0001   4.03\       \<0.0001
                                           2.73-9.45                      1.64-3.43              1.93-6.18              2.65-6.25   
  --------------------------------------------------------------------------------------------------------------------------------------------

CEA: Carcinoembryonic antigen, CI: confidence interval, HR: hazard ratio, Mucinous: mucinous adenocarcinoma, NS: Not significant, Poorly: poorly differentiated adenocarcinoma, SAR: survival after recurrence.

DISCUSSION {#s3}
==========

We evaluated the clinicopathological factors associated with TTR and SAR in patients with CC and RC, as critical factors for guiding appropriate follow-up after curative surgery \[[@R3]--[@R5]\]. Appropriate follow-up after curative surgery has been proposed by TTR or the accumulative recurrence rate, but not SAR.

The recurrence rate in this study (16.3%) was similar to those in previous studies \[[@R3], [@R7]\]. The recurrence rate in stage I CC patients was only 1.2%, so we excluded these patients from analysis of TTR and SAR. The recurrence rate in stage I RC patients was 8.4%, and the accumulative recurrence rates were 16.7% and 64.8% at 1 and 3 years, respectively. Therefore, stage I RC patients may require different surveillance from stage II and III patients. We also excluded stage I RC patients for further analysis of TTR and SAR.

Among stage II and III patients, the accumulative recurrence rate was about 50% at 1 year, which was higher than in some previous reports, but similar to that in the FACS trial involving intensive surveillance, including CT \[[@R3], [@R7]\]. The 2- and 3-year recurrence rates in patients with stages II and III were 70%--80% and 80%--90%, respectively. These are similar to the previous data by Kobayashi et al and suggest that intensive surveillance with CEA checks every 3 months are necessary for at least 3 years, in contrast to the NCCN recommendation of 2 years \[[@R3], [@R14], [@R15]\].

TTR differed significantly between CC and RC in stage III patients. Predictors for TTR were different between CC and RC. In CC, patients with high preoperative CEA level and lymphovascular invasion could be followed-up as candidates for early recurrence. On the other hand, predictors in RC were venous invasion and liver metastasis. Therefore, follow-up in RC should include CT to evaluate liver metastasis.

Our data showed that predictors for TTR were not prognostic factors for SAR. Short TTR has been previously reported to influence survival in small cases of study \[[@R16], [@R17]\]. In this study, recurrence within 1 year was an independent prognostic factor for poor SAR in stage III RC patients. Age (≥75), type of recurrence (M1b), and treatment after recurrence (surgical resection) were also identified as independent prognostic factors for SAR in the current study. Surgical resection was considered a strong prognostic factor for advanced CRC \[[@R18], [@R19]\]. Recent improvement of treatments against metastatic CRC may provide better SAR than that in current study \[[@R20], [@R21]\].

Therefore, we proposed that patients with prognostic factors for poor SAR should receive intensive treatment and follow-up after curative surgery. These patients include stage III CC patients with undifferentiated adenocarcinoma or N2 nodal status, stage II RC patients with high preoperative CEA level, and stage III RC patients.

Our study had several limitations. First, it was a retrospective study, and we had no genetic information, such as RAS mutation and microsatellite instability statuses, which are critical genetic markers for prognosis and treatment. KRAS mutation analysis has been available for clinical use in Japan since 2010. Moreover, universal screening for Lynch syndrome was performed in \<10% of the hospitals specializing in CRC treatment in Japan \[[@R22]\]. Genetic information was therefore not considered for CRC treatment at the time of surgery in this study. Second, this study also lacked information on the usage of molecular-targeted drugs. Vascular endothelial growth factor and epidermal growth factor antibodies have been used clinically in Japan since 2007 and 2008, respectively. Patients with recurrence should thus have received these drugs for treatment after recurrence. Finally, this was a retrospective study with no rules about follow-up or treatment after surgery, or treatment after recurrence.

Although it seems advisable to detect recurrence as soon as possible to improve the chances of curative resection, the usefulness of intensive follow-up remains controversial. Furthermore, it is unclear if early detection of recurrence could increase the rate of curative treatment and improve survival. Our data demonstrated that short TTR was an independent prognostic factor for SAR in stage III RC patients, who should have received intensive follow-up. However, further prospective studies are needed to confirm our results. Genetic assessment is indispensable in the era of molecular-targeted therapy.

MATERIALS AND METHODS {#s4}
=====================

Patients and data collection {#s4_1}
----------------------------

This retrospective multicenter study was conducted by the Japanese Study Group for Postoperative Follow-up of Colorectal Cancer (JFUP-CRC). Clinical data were collected for CRC patients who underwent curative surgery at 22 hospitals in Japan between 2007 and 2008. The study was approved by the institutional review board or ethics committee at each hospital and was performed according to the Declaration of Helsinki and Ethical Guidelines for Clinical Research. All patients provided written informed consent. The JFUP-CRC office pooled and prepared the data available for clinical study, as described in the 7^th^ edition of the Japanese Classification of Colorectal Carcinoma \[[@R23]\]. Lymphatic (ly) or venous (v) invasion was classified according to the degree of invasion, as follows: no invasion (ly0/v0), minimal invasion (ly1/v1), moderate invasion (ly2/v2), or severe invasion (ly3/v3). A total of 4992 CRC patients who underwent curative resection in 2007 and 2008, without preoperative chemotherapy/radiotherapy, hereditary CRC, lateral lymph node metastasis, or colitic cancer, were considered suitable for assessment. These patients usually received follow-up with CEA tests every 3 months and CT every 6 months for 3 years, and then CEA every 6 months and CT every 12 months for 3--5 years. The median follow-up time was 72 months in all patients and 60 months in patients with recurrence.

Data analysis {#s4_2}
-------------

Differences in clinicopathological factors according to tumor location (CC or RC) were analyzed for all patients and for patients with recurrence. Factors associated with recurrence were assessed using χ^2^ tests.

The influences of clinicopathological factors on relapse-free survival (RFS) and overall survival (OS) in all patients, and TTR and SAR in patients with recurrence were assessed using log-rank tests. Prognostic factors associated with TTR and SAR were subjected to multivariate analyses using a Cox proportional hazard model or logistic analysis. A *P* value of \<0.05 was considered significant for all analyses.

CONCLUSIONS {#s5}
===========

We recommend that intensive follow-up after surgery is appropriate in stage III CC patients with undifferentiated adenocarcinoma or N2 nodal status, stage II RC patients with high preoperative CEA level, and stage III RC patients.
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